Myrexis cancer news
Myrexis also said that NASDAQ initiated proceedings to delist the company due to its belief that Myrexis is a "public shell" and the resignation of all the company's independent directors. The company could not be reached for details.
Last September, Myrexis terminated a 2003 deal and returned rights to cancer compound Azixa verubulin to EpiCept Corp. (OTCQX:EPCT; SSE:EPCT, Tarrytown, N.Y.). The small molecule microtubule destabilizing apoptosis-inducer was in Phase IIb testing for glioblastoma multiforme (GBM). In March 2012, Myrexis said it would reduce headcount to 10 by June 30, 2012. The move followed a February announcement that the company retained Stifel to evaluate strategic alternatives and suspended development of all its preclinical and clinical programs (see BioCentury, March 12, 2012 & Sept. 10, 2012). ...